UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: Incidence of Blindness and Sight Impairment in Ranibizumab-Treated Patients

Ophthalmology

Volumn 123, Issue 11, 2016, Pages 2386-2392

  Johnston, Robert L ^a   Lee, Aaron Y ^b,c   Buckle, Miranda ^e   Antcliff, Richard ^d   Bailey, Clare ^e   McKibbin, Martin ^f   Chakravarthy, Usha ^g   Tufail, Adnan ^c  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

^d ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST   (United Kingdom)

^e BRISTOL EYE HOSPITAL   (United Kingdom)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; AGED; BLINDNESS; CONFERENCE PAPER; ELECTRONIC MEDICAL RECORD SYSTEM; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; UNITED KINGDOM; VISUAL ACUITY; VISUAL ACUITY CHART; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; ELECTRONIC HEALTH RECORD; INTRAVITREAL DRUG ADMINISTRATION; MULTICENTER STUDY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; BLINDNESS; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MALE; RANIBIZUMAB; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84994894097     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2016.07.037     Document Type: Conference Paper

References (29)

1. 1 Buch, H., Vinding, T., La Cour, M., et al. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults. Ophthalmology 111 (2004), 53–61.
2. 2 Resnikoff, S., Pascolini, D., Etya'ale, D., et al. Global data on visual impairment in the year 2002. Bull World Health Organ 82 (2004), 844–851.
3. 3 Bressler, N.M., Age-related macular degeneration is the leading cause of blindness. JAMA 291 (2004), 1900–1901.
4. 4 Bunce, C., Wormald, R., Causes of blind certification in England and Wales: April 1999–March 2000. Eye 22 (2004), 905–911.
5. 5 Skaat, A., Chetrit, A., Belkin, M., Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol 153 (2012), 214–221.
6. 6 Brown, D.M., Kaiser, P.K., Michels, M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006), 1432–1444.
7. 7 Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006), 1419–1431.
8. 8 National Institute for Health and Care Excellence. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. NICE technology appraisal guidance 155. https://www.nice.org.uk/Guidance/ta155. Accessed August 21, 2015.
9. 9 Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The Neovascular Age-Related Macular Degeneration Database: multicenter study of 92 976 ranibizumab injections. Ophthalmology 121 (2014), 1092–1101.
10. 10 Campbell, J.P., Bressler, S.B., Bressler, N.M., Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol 130 (2012), 794–795.
11. 11 Bloch, S., Larsen, Munch, I., Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 153 (2012), 209–213.
12. 12 Rostron, E., McKibbin, M., Visual impairment certification secondary to ARMD in Leeds 2005–2010: is the incidence falling?. Eye 26 (2012), 933–936.
13. 13 Bressler, N.M., Doan, Q.V., Varma, R., et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularisation: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol 129 (2011), 709–717.
14. 14 Robinson, R., Deutsch, J., Jones, H., et al. Unrecognised and unregistered visual impairment. Br J Ophthalmol 78 (1994), 736–740.
15. 15 Barry, R., Murray, P., Unregistered visual impairment: is registration a failing system?. Br J Ophthalmol 89 (2005), 995–998.
16. 16 Malik, A.N., Bunce, C., Wormald, R., et al. Geographical variation in certification rates of blindness and sight impairment in England, 2008–2009. BMJ Open, 2, 2012.
17. 17 Varma, R., Bressler, N.M., Doan, Q.V., et al. Visual impairment and blindness avoided with ranibizumab in Hispanic and non-Hispanic whites with diabetic macular edema in the United States. Ophthalmology 122 (2015), 982–989.
18. 18 Linder, M., Chang, T.S., Scott, I.U., et al. Validity of the visual function index (VF-14) in patients with retinal disease. Arch Ophthalmol 117 (1999), 1611–1616.
19. 19 Bressler, N.M., Chang, T.S., Suner, I.J., et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 117 (2010), 747–756.
20. 20 World Health Organization. International Statistical Classification of Diseases and Related Problems, 10th revision, 2010 edition. 2011, WHO Press, Geneva, Switzerland http://www.who.int/classifications/icd/ICD10Volume2_en_2010.pdf Accessed March 7, 2015.
21. 21 TAP and VIP Study Groups. Effect of lesion size, VA, and lesion composition on VA change with and without verteporfin therapy for choroidal neovascularisation secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 136 (2003), 407–418.
22. 22 TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin. Arch Ophthalmol 117 (1999), 1329–1345.
23. 23 Harding, S.P., Tomlin, K., Reeves, B.C., et al. Verteporfin photodynamic therapy cohort study: report 1: effectiveness and factors influencing outcomes. Ophthalmology 116 (2009), 1–8.
24. 24 Regillo, C.D., Brown, D.M., Abraham, P., et al. Randomised, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145 (2008), 239–248.
25. 25 Bandello, F., Lafuma, A., Berdeaux, G., Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity. IOVS 48 (2007), 96–103.
26. 26 Bressler, N.M., Bressler, S.B., Congdon, N.G., et al. Potential public health impact of age-related eye disease study results: AREDS report no. 11. Arch Ophthalmol 121 (2003), 1621–1624.
27. 27 Gillies, M.C., Walton, R.J., Arnold, J.J., et al. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. Ophthalmology 121 (2014), 676–681.
28. 28 Freund, K.B., Korobelnik, J.F., Devenyi, R., et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina 35 (2015), 1489–1506.
29. 29 Rofagha, S., Bhisitkul, R.B., Boyer, D.S., et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA and HORIZON. Ophthalmology 120 (2013), 2292–2299.